The Simple Reality of Apparatus 4
Three basic questions must be answered in order to begin USP Apparatus 4 method development. They are:
• v\That is the product form -tabl et, capsu le, powder, implant, etc.?
• What is the relative solubility of the product?
• \oVhat is the expected time of dissolution?

What is the product form?
In genera l, the product form will dictate the hardware configuration of the syste m -i.e., the cell that is most appropriate. Selection of ce ll type is the first and probably the si mpl est decision 111 the method development process. As pointed Ollt in my previous article ( l), there ,He five types of cel ls that are currently avai lable. By far the most common cell s are the "sta ndard " 12mm and 22.6mm ce lls that are genera lly used to accommodate tablets, caplets, 3nd capsul es. Tn these cells, the product sa mpl e is placed in .1 ho lder within the cell and a filter system is placed downstream from the product. 
What is the relative solubility of the product?
Many people will consider Apparatus 4 simply because of the poor solubility of their product. The basket and paddle methods (USP Apparatus I and 2, respectively) are limited in their ability to handle many poorly soluble products because of the limited media volume that they accommodate. Obviously, flow characteristics can greatly affect the ability of Apparatus 4 to address the solubility problem. Optimizing ti,e rate of the continuously flowing fresh media across the sample allows for the exposure of the sample to a substantially increased volume of fresh media that increases the sample solubility. Most method development will start with the USP recommended 16mL/min flow rate. The flow rate can be increased to improve solubility of the product. The flow rate can be decreased, if necessary, to conserve media.
What is the total dissolution time?
Another primary reason Apparatus 4 may be considered is its ability to make on-line ( with changi ng the media in US P Apparatus I and 2 systc ms (product loss, co nt:llllin atio n, incomplcte change), arc overcomc.
final Consideration
Th e fin al consid erati o n in deve lo ping ,1n Apparatus 4 m etho d is the applicability of automation. US P 4 ca n be conducted by Immual proced ures o r ca n be batch : : lUtomated for Illultipl e unattend ed analyses. Samples ca n he co llected to a fraction coll ector or anal yzed online. Data C::1I1 be analyzed , o rga nized, reported, archi ved , and reca ll ed in a V:1rie ly o f ways. The cost.o;; of automation are, of course, cOlllm ensurate with t he sophi stication , bUl usually the added effi ciency is g reater than the investment.
